Robert Eckert - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Independent Director

Mr. Robert A. Eckert is Lead Independent Director of Amgen Inc. Robert A. Eckert was an Operating Partner at Friedman Fleischer Lowe, a private equity firm, since September 2014. Mr. Eckert was the Chief Executive Officer of Mattel, Inc., a toy design, manufacture and marketing company, having held this position from 2000 through December 2011, and its Chairman of the Board from 2000 through 2012. He was President and Chief Executive Officer of Kraft Foods Inc., a consumer packaged food and beverage company, from 1997 to 2000, Group Vice President from 1995 to 1997, President of the Oscar Mayer Foods Division from 1993 to 1995 and held various other senior executive and other positions from 1977 to 1992. Mr. Eckert was a director of McDonalds Corporationrationration, a company which franchises and operates McDonalds restaurants in the global restaurant industry, since 2003, serving as the Chair of the Compensation Committee and a member of the Executive and Governance Committees. Mr. Eckert was a director of Smart Final Stores, Inc., a warehouse store, from May 2013 until July 2014 prior to it becoming a publiclytraded company. Mr. Eckert also has served as a director of Levi Strauss Co., a privatelyheld jeans and casual wear manufacturer, since 2010. He was appointed director of Eyemart Express Holdings LLC, a privatelyheld eyewear retailer and portfolio company of Friedman Fleischer Lowe, in 2015. Mr. Eckert is on the Global Advisory Board of the Kellogg School of Management at Northwestern University and serves on the Eller College National Board of Advisors at the University of Arizona
Age: 61  Director Since 2016      
805-447-1000  http://www.amgen.com
Eckert received an undergraduate degree from the University of Arizona and a master?s degree in business administration from the Kellogg School of Management at Northwestern University.

Robert Eckert Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Kathi SeifertEli Lilly and Company
1995
Paul CarterMallinckrodt Public Limited Com
2018
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Nancy HutsonEndo International plc
2009
Ellen MarramEli Lilly and Company
2013
Douglas IngramEndo International plc
2016
Gregory HinckleyBio Rad Laboratories
2017
Karen VousdenBristol Myers Squibb Company
2018
Virgil ThompsonMallinckrodt Public Limited Com
2014
David HooverEli Lilly and Company
2009
Arnold PinkstonBio Rad Laboratories
2017
Vicki SatoBristol Myers Squibb Company
2017
Craig ThompsonMerck Co
2008
Leslie BrunMerck Co
2016
Roxanne AustinAbbott Laboratories
2000
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Patricia RussoMerck Co
1995
William KaelinEli Lilly and Company
2012
Daniel StarksAbbott Laboratories
2017
Peter WendellMerck Co
2003
James FarrellAbbott Laboratories
2006

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Current Sentiment - AMGN

Amgen Investor Sentiment
Majority of Macroaxis users are presently bullish on Amgen. What is your sentiment towards investing in Amgen? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.